TY - JOUR AU - Carlo Visco, AU - Alexander Tzankov, AU - Zijun Y. Xu-Monette, AU - Roberto N. Miranda, AU - Yu Chuan Tai, AU - Yan Li, AU - Wei-min Liu, AU - Emanuele S. G. d'Amore, AU - Yong Li, AU - Santiago Montes-Moreno, AU - Karen Dybkær, AU - April Chiu, AU - Attilio Orazi, AU - Youli Zu, AU - Govind Bhagat, AU - Huan-You Wang, AU - Cherie H. Dunphy, AU - Eric D. His, AU - X. Frank Zhao, AU - William WL. Choi, AU - Xiaoying Zhao, AU - J. Han van Krieken, AU - Qin Huang, AU - Weiyun Ai, AU - Stacey O'Neill, AU - Maurilio Ponzoni, AU - Andres JM. Ferreri, AU - Brad S. Kahl, AU - Jane N. Winter, AU - Ronald S. Go, AU - Stephan Dirnhofer, AU - Miguel A. Piris, AU - Michael B. Møller, AU - Lin Wu, AU - L. Jeffrey Medeiros, AU - Ken H. Young, PY - 2013/01/31 Y2 - 2024/03/28 TI - Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study JF - Haematologica JA - haematol VL - 98 IS - 2 SE - Articles DO - 10.3324/haematol.2012.066209 UR - https://haematologica.org/article/view/6562 SP - 255-263 AB - Diffuse large B-cell lymphoma can be classified by gene expression profiling into germinal center and activated B-cell subtypes with different prognoses after rituximab-CHOP. The importance of previously recognized prognostic markers, such as Bcl-2 protein expression and BCL2 gene abnormalities, has been questioned in the new therapeutic era. We analyzed Bcl-2 protein expression, and BCL2 and MYC gene abnormalities by interphase fluorescence in situ hybridization in 327 patients with de novo disease treated with rituximab-CHOP. Isolated BCL2 and MYC rearrangements were not predictive of outcome in our patients as a whole, but only in those with the germinal center subtype of lymphoma. The prognostic relevance of isolated MYC rearrangements was weaker than that of BCL2 isolated translocations, but was probably limited by the rarity of the rearrangements. Seven of eight patients with double hit lymphoma had the germinal center subtype with poor outcome. The germinal center subtype patients with isolated BCL2 translocations had significantly worse outcome than the patients without BCL2 rearrangements (P=0.0002), and their outcome was similar to that of patients with the activated B-cell subtype (P=0.30), but not as bad as the outcome of patients with double hit lymphoma (P